Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments

Not Applicable

Recruiting

• Conditions: Chronic Disease
• Interventions: Other: Mutlidisciplinary medication Review (MMR); Other: Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up

• Registration Number: NCT03827031
• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Brief Summary

The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-08-22
• Study First Submitted QC: 2019-01-30
• Study First Posted: 2019-02-01
• Study Start: 2022-07-18
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-13
• Primary Completion: 2025-07
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 297

Inclusion Criteria

• The patient (or their representative) has given his consent and signed the consent form.
• The patient is affiliated to a health insurance programme.
• The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
• The patient is available for a follow-up of 3 months.
• The patient is hospitalized in the surgery department.
• Patient with a Trivalle score greater than or equal to 2 (≥).
• Patient living in a nursing home or going back home after hospitalization.

Exclusion Criteria

• The subject is participating in another category I interventional study.
• The subject is in an exclusion period determined by another study.
• The subject is under safeguard of justice.
• It is not possible to give the patient (or his/her trusted-person) informed information.
• Palliative care

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B1 interventional group	Mutlidisciplinary medication Review (MMR)	-
B2 interventional group	Mutlidisciplinary medication Review (MMR)	-
B2 interventional group	Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up	-

Primary Outcome Measures

Name	Time	Method
Change in iatrogenic drug risk in intervention groups versus control group	3 months after hospitalization	Proportion of patients transitioning from intermediate or high to low risk according to Trivalle score (a score between 0-10. A score 0-1 constitutes a low ADE risk (12%), score 2-5 represents an average risk (32%), and a score 6-10 represents a high risk (53%)

Secondary Outcome Measures

Name	Time	Method
Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group	Hospital discharge (maximum 30 days)
Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent	3 months after hospital discharge	Number of modifications accepted/number of modifications proposed
Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2)	Hospital discharge (maximum 30 days)	Hours
Time required for ransmitting multidisciplinary correspondence documents in B2 group	Hospital discharge (maximum 30 days)	Hours
Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group	2 months post discharge
Mortality rate in each group	3 months after hospital discharge
Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group	Hospital discharge (maximum 30 days)	email, fax or letter
Rate of patients with at least one rehospitalization in each group	3 months after hospital discharge
patient satisfaction in all groups (A, B1, B2)	3 months after hospital discharge	questionnaire
Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups	Hospital discharge (maximum 30 days)	Number of modifications accepted/number of modifications proposed
Number of potentially inappropriate medications per patient in each group	3 months after hospital discharge
Number of multidisciplinary correspondence documents sent to the community acotors in B2 group	Hospital discharge (maximum 30 days)
Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2	2 months post hospital discharge
Healthcare team satisfaction in interventional groups (B1, B2)	3 months after hospital discharge	Custom-built 7-part questionnaire

Trial Locations

Locations (4)

Chu de Grenoble; 🇫🇷 Grenoble, France

CHU de Montpellier; 🇫🇷 Montpellier, France

Nimes University Hospital; 🇫🇷 Nîmes, France

CHU de Toulouse; 🇫🇷 Toulouse, France